Skip to main content

Neuroendocrine Neoplasm clinical trials at UCSF
1 in progress, 0 open to new patients

  • Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases

    Sorry, not yet accepting patients

    This pilot phase II trial studies how well pembrolizumab and liver-directed therapy works in treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Liver-directed therapies such as radiofrequency ablation, transarterial embolization, yttrium-90 microsphere radioembolization, and cryoablation may help to shrink tumors that are not being directly targeted. Giving pembrolizumab and liver-directed therapy may work better in treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver.

    San Francisco, California